We are building a pipeline of oral therapies designed to address immune dysfunction, and in advancing these therapies, we aim to transform the treatment paradigm – and the lives – of people living with immune-mediated diseases.
Our TYK2 franchise is led by ESK-001, a potentially best-in-class TYK2 inhibitor currently in clinical development for psoriasis, systemic lupus erythematosus (SLE), and uveitis. This highly validated target has the potential to effectively treat multiple immune-mediated indications.
We are also developing A-005, a first-in-class, CNS-penetrating, allosteric TYK2 inhibitor for neuro-inflammatory diseases such as Multiple Sclerosis.
Beyond TYK2, we have several early-stage discovery assets, comprised of targets identified by our data analytics platform, for the potential treatment of immune-mediated indications.
Potential best-in-class allosteric TYK2 inhibitor with superior PK/PD profile
Our lead candidate ESK-001, a highly selective and potentially best in class tyrosine kinase 2 (TYK2) inhibitor is being evaluated in Phase 2 clinical trials for the treatment of patients with moderate to severe plaque psoriasis, systemic lupus erythematosus (SLE), and uveitis.
ESK-001 is designed to have greater selectivity for TYK2 over JAK1 compared to currently available treatments or therapies in clinical development. In the company’s Phase 1 studies, ESK-001 demonstrated selective, full and sustained inhibition of TYK2, with no pharmacological inhibition of JAK1/2/3 and no observed JAK-related safety events to date. ESK-001 was well-tolerated in these studies, with no serious adverse events observed.
Alumis anticipates reporting Phase 2 clinical data for ESK-001 from the STRIDE clinical trial in patients with moderate to severe plaque psoriasis at a future medical meeting.
Potential first-in-class brain penetrant allosteric TYK2 inhibitor for the treatment of neuroinflammatory diseases
We are also developing A-005, our second TYK2 inhibitor with differentiated properties for neuro-inflammatory diseases. Our data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the central nervous system (CNS). We believe that this represents a significant breakthrough as there are no TYK2 inhibitors currently approved or in clinical development targeting the CNS.
Additional Programs / Discovery Efforts
Beyond TYK2, we have several early-stage discovery assets comprised of targets identified by our data analytics platform for the potential treatment of immune-mediated indications.